Summit Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics Net Debt Growth & History (SMMT)
Summit Therapeutics's net debt was −$204.4M for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$204.4M | −$106.7M | — |
| 2024 | 2024-12-31 | −$97.6M | −$32.3M | — |
| 2023 | 2023-12-31 | −$65.3M | $278.8M | — |
| 2022 | 2022-12-31 | −$344.2M | −$275.1M | — |
| 2021 | 2021-12-31 | −$69.0M | −$3.1M | — |
| 2020 | 2020-12-31 | −$66.0M | −$3.0M | — |
| 2019 | 2019-12-31 | −$62.9M | — | — |
Summit Therapeutics quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$399.0M | −$106.7M | — |
| Q1 2026 | 2026-03-31 | −$86.5M | $118.6M | — |
| Q4 2025 | 2025-12-31 | −$204.4M | −$106.7M | — |
| Q3 2025 | 2025-09-30 | −$233.1M | −$147.3M | — |
| Q2 2025 | 2025-06-30 | −$292.3M | −$272.6M | — |
| Q1 2025 | 2025-03-31 | −$205.1M | −$153.3M | — |
| Q4 2024 | 2024-12-31 | −$97.6M | −$32.3M | — |
| Q3 2024 | 2024-09-30 | −$85.8M | −$68.6M | — |
| Q2 2024 | 2024-06-30 | −$19.7M | $15.1M | — |
| Q1 2024 | 2024-03-31 | −$51.8M | $15.0M | — |
| Q4 2023 | 2023-12-31 | −$65.3M | $278.8M | — |
| Q3 2023 | 2023-09-30 | −$17.1M | $100.5M | — |
| Q2 2023 | 2023-06-30 | −$34.9M | $20.5M | — |
| Q1 2023 | 2023-03-31 | −$66.8M | $8.2M | — |
| Q4 2022 | 2022-12-31 | −$344.2M | −$275.1M | — |
| Q3 2022 | 2022-09-30 | −$117.6M | −$39.2M | — |
| Q2 2022 | 2022-06-30 | −$55.3M | $45.9M | — |
| Q1 2022 | 2022-03-31 | −$75.0M | $25.8M | — |
| Q4 2021 | 2021-12-31 | −$69.0M | −$3.1M | — |
| Q3 2021 | 2021-09-30 | −$78.4M | −$57.7M | — |
| Q2 2021 | 2021-06-30 | −$101.2M | — | — |
| Q1 2021 | 2021-03-31 | −$100.8M | — | — |
| Q4 2020 | 2020-12-31 | −$66.0M | −$3.0M | — |
| Q3 2020 | 2020-09-30 | −$20.7M | — | — |
| Q4 2019 | 2019-12-31 | −$62.9M | — | — |
Summit Therapeutics net debt trends
Over the last five fiscal years, Summit Therapeutics's net debt decreased from −$66.0M to −$204.4M, a change of −$138.4M. The latest reported quarter, Q2 2026, shows −$399.0M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗